Directly target IGF2BP1 and block its recognition of m6A, thereby inducing apoptosis of cancer cells in vivo, activating immune cells into the TME and reducing PD-L1 expression in HCC. The gene discussed is IGF2BP1; the disease is hepatocellular carcinoma.